Biosimilar monoclonal antibody market will reach $3,229m in 2018

Friday 30 August 2013, Amsterdam

A new report predicts the world biosimilar monoclonal antibody (mAbs) market will generate $3,229m in 2018. That drug industry earned $61.88m in 2012, according to Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023, published in July 2013.

We predict the biosimilar mAbs industry will achieve high sales growth from 2013 to 2023, as the first products are launched in the world’s developed pharmaceutical markets. The strength of that follow-on biologics industry stems from the need for governments and healthcare payers to cut costs. Biosimilar mAbs represent important opportunities to reduce spending.

Jennifer Taylor, a pharmaceutical industry analyst, said: “The biosimilar mAb market is currently in its infancy; there is only one product that is officially recognised as a biosimilar mAb on the market. It is approved in South Korea. However, the industry is on the verge of rapid expansion, with approval of the first products in the EU expected imminently. With monoclonal antibody therapies accounting for five of the top ten drugs by revenue in 2012, there is high revenue potential in the industry. Biosimilar versions of each of the leading mAb therapies of 2012 are expected to reach the market by 2018. This means rapid growth in the industry will be seen during the first half of our forecast period.

“During the second half of our forecast period, revenue growth will slow as a result of competition in the market. The R&D pipeline is well stocked, with multiple biosimilar versions of each of the leading mAb therapies in development. The competition between these products will restrict revenue growth.”

This new report shows revenue forecasts to 2023 at overall world market and submarket levels. It predicts individual biosimilar revenues of these molecules:

• Infliximab
• Rituximab
• Adalimumab
• Trastuzumab
• Bevacizumab
• Abciximab
• Other compounds (grouped analysis).

The study also forecasts revenues of 13 products on the market and in the R&D pipeline, including these agents: Celltion’s Remsima, CT-P10 and CT-P06; Epirus Biopharmaceuticals’ BOW-015; Dr Reddy’s Reditux; Boehringer Ingelheim’s BI695500 and BI695501; Fujifilm Kyowa Kirin Biologics’ versions of adalimumab and bevacizumab.

The analyses also cover the US, Japan, Germany, France, Italy, the UK, Spain (EU5), Brazil, Russia, India and China (BRIC), as well as South Korea. The study gives overall revenue forecasts to 2023 for those countries. Also, the leading companies in the industry are discussed and research interviews with the industry presented.

Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023 adds to visiongain’s range of analytical reports on industries and markets in healthcare.